Arbutus receives regulatory approval to initiate a phase 1a/1b clinical trial with ab-836, an oral capsid inhibitor for the treatment of chronic hepatitis b infection

Warminster, pa., march 16, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis b virus (hbv) infection, as well as therapies to treat coronaviruses (including covid-19), today announced that it has received regulatory approval to initiate a phase 1a/1b clinical trial with ab-836, its proprietary oral capsid inhibitor for the treatment of hbv infection.
ABUS Ratings Summary
ABUS Quant Ranking